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ABSTRACT
The time the free drug serum concentration of antibiotic remains above the pathogen MIC (T > MIC)
determines bacteriological efﬁcacy and emergence or selection of resistance for penicillin and
amoxicillin with or without clavulanate. Multiple studies in animal and in-vitro models now support
this conclusion. The size of the T > MIC (the pharmacokinetic ⁄ -dynamic target) is > 40–50% to
maximise antibacterial effect and pathogen eradication for Streptococcus pneumoniae and probably also
Haemophilus inﬂuenzae. The size of the T > MIC for optimal antibacterial effect is changed by host
immune status but not by bacterial inoculum or mechanism of resistance. There is good animal evidence
to support the prediction that, as long as the target T > MIC is achieved, strains of S. pneumoniae with
amoxicillin MICs of 0.016 mg ⁄L will respond to amoxicillin in the same way as those with MICs of
1–2 mg ⁄L. Emergence of resistance to amoxicillin ⁄ clavulanate in S. pneumoniae is related to low T > MIC
(< 20%) and also to the degree of population heterogeneity to amoxicillin. Selection of resistant strains of
S. pneumoniae is also related to T > MIC. Monte Carlo simulations based on the pharmacokinetics
of amoxicillin with or without clavulanate in humans are needed to best predict the likely efﬁcacy of
different amoxicillin dosing regimens. This approach adequately allows the considerable pharmaco-
kinetic variability in amoxicillin handling by infected patients to be accounted for as well as differences
in pathogen b-lactam susceptibility.
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GENERAL PHARMACODYNAMIC
PROPERTIES OF b-LACTAMS
The pharmacodynamic characteristics of b-lactam
antibiotics are now well established. These are:
(i) nonconcentration or time-dependent killing at
drug concentrations in the therapeutic range;
(ii) minimal-to-moderate persistent antibiotic ef-
fects; (iii) the pharmacokinetic goal of dosing being
to maximize the duration of drug exposure; and
(iv) the dominant pharmacodynamic index being
the time that the free drug concentration remains
above some threshold concentration—usually the
time above the pathogen MIC (T > MIC) [1].
In-vivo, using a neutropenic murine lung or
thigh infection model with over 200 b-lactam
dose–response studies and a range of pathogens,
it has been possible to show that the T > MIC for
a deﬁned antibacterial effect endpoint varies
within the b-lactam family and between pathogen
groups. The mean T > MIC to produce a 24-h
bacteriostatic effect was 20–26% for carbapenems,
29–34% for penicillins and 35–55% for cephalo-
sporins [2]. In addition, the T > MIC for a static
effect was lower against staphylococci (24 ± 9%)
than streptococci (41 ± 12%). More recently, it has
been proposed that b-lactams could be reclassi-
ﬁed according to their pharmacodynamic
properties [3].
PHARMACODYNAMIC PROPERTIES
OF PENICILLINS AGAINST
STREPTOCOCCUS PNEUMONIAE
Penicillins such as phenoxymethyl and benzyl
penicillin, ampicillin and amoxicillin with or
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without clavulanate show nonconcentration-
dependent killing of Streptococcus pneumoniae,
with signiﬁcant bacterial killing over 24 h [4,5].
In-vitro, penicillin exhibits a postantibiotic effect
against S. pneumoniae; however, it has not been
possible to reproduce a postantibiotic effect in a
mouse thigh model in-vivo. This may be related
to the pharmacokinetics of penicillin in mice. In
contrast, ampicillin has a postantibiotic effect of
1–4 h in-vivo, which increases with increasing
duration of drug exposure [6,7].
Studies in animal pharmacodynamic models
have conﬁrmed that for S. pneumoniae treated with
penicillin the T > MIC is the dominant pharmaco-
dynamic index [8,9]. As well as deﬁning the
dominant pharmacodynamic index, however, it is
necessary to determine the size of the index for
best effect, because this then becomes the phar-
macodynamic target of therapy (Fig. 1). The
process in Fig. 1 is now the paradigm used to
develop or assess antimicrobials for clinical use. A
knowledge of the dominant pharmacodynamic
index deﬁnes the target that can be used in Monte
Carlo simulations and to set doses for clinical
studies. Subsequently, data from clinical trials can
be used to conﬁrm the size of the pharmacody-
namic index required for clinical or bacteriologi-
cal cure in humans as well as to provide further
and more clinically relevant clinical data for
conﬁrmatory and comparative Monte Carlo
simulations.
A number of factors are known to affect the size
of the pharmacodynamic index. These are:
(i) mechanism of antibiotic resistance, if present;
(ii) bacterial inoculum; (iii) species treated;
(iv) host immune status; and (v) choice of antibac-
terial endpoint (i.e. bacteriostatic or bactericidal).
Although the mechanism of resistance seems to
be important in treating S. pneumoniae with some
drug classes, this is not so for penicillins [10].
Furthermore, for both penicillin-susceptible (MIC
0.016 mg ⁄L) and penicillin-nonsusceptible (MIC
1.0 mg ⁄L) S. pneumoniae, the antibacterial effect of
penicillin in neutropenic lung or thigh infection
and in-vitro models was the same for similar
T > MIC values [9,11]. In addition, low (106
CFU ⁄mL) or high (108 CFU ⁄mL) inocula of
S. pneumoniae used in an in-vitro pharmacokinetic
model had no effect on the amoxicillin ⁄ clavula-
nate T > MIC required to produce the EC50 or
80% of the maximum response [12].
There is little information on the effect of
bacterial species on the T > MIC required for
penicillins. In-vivo animal data in a neutropenic
rat pneumonia model and similar work performed
in an in-vitro pharmacokinetic model indicate that
the amoxicillin ⁄ clavulanate T > MICs for bacterio-
static effects, or 80% or 95% of the maximum
effect, are similar for S. pneumoniae and Haemo-
philus inﬂuenzae (G. Woodnutt, personal commu-
nication) [12].
In contrast, host immune status has a signiﬁ-
cant effect on the size of the pharmacodynamic
index. The absence of white blood cells in a
murine S. pneumoniae infection model increases
the T > MIC to produce a 2-log bacterial kill from
25% to 35% [13]. Similar effects also occur for
S. pneumoniae treated with clindamycin or doxy-
cycline in murine models [14]. If, instead of
immunocompromising the infected animal, the
immunity is augmented by the use of speciﬁc
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Fig. 1. Deﬁning the pharmacodynamic target for therapy.
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antibodies to S. pneumoniae, the minimal protect-
ive dose of amoxicillin and the T > MIC are
signiﬁcantly reduced [15,16].
The most signiﬁcant factor in determining the
size of the pharmacodynamic index is the choice
of antibacterial endpoint. The b-lactam T > MIC
will be larger for a 2-log bacterial kill than for a
24-h static effect, while the T > MIC for a 4- or
6-log kill over 24 h will be greater still (Fig. 2).
Most of the information on the size of the
T > MIC for the antibacterial effect of penicillin
or amoxicillin with or without clavulanate comes
from neutropenic animal pneumonia or thigh
infection models. The T > MIC for a bacteriostatic
effect after 6 or 24 h of treatment ranges from 16%
to 40%, while the maximum effect occurs at
40–80%. Such experiments have been performed
in a wide range of models, such as murine lung
and thigh, rat pneumonia, and rabbit tissue cage
experiments [8,9,17,18]. Data from in-vitro models
are also in agreement because the T > MIC for
amoxicillin ⁄ clavulanate against S. pneumoniae is
5–15% for a static effect and 41–46% for a 90%
maximal effect [19].
In a neutropenic rat model of H. inﬂuenzae
pneumonia, the T > MIC for an amoxicillin ⁄ cla-
vulanate static effect was 23% and for a 95%
maximal effect was 32%. Values derived from
in-vitro models were similar, with an 80%
maximal effect occurring at 20–48% (G. Woodnutt
and V. Berry, personal communication) [19].
Lowden et al. reported somewhat different ﬁnd-
ings in their in-vitro model, with a T > MIC of
< 50% being insufﬁcient for amoxicillin ⁄ clavula-
nate to eradicate H. inﬂuenzae within 24 h, but a
T > MIC of 73–79% producing the best pathogen
eradication [20].
By analogy with the antibacterial effect of
ﬂuoroquinolones in pneumococcal respiratory
infection, it would appear that the size of the
pharmacodynamic index that best correlates with
clinical outcome in mild-to-moderate pneumonia
is that required to produce a 24-h bacteriostatic
effect or a 1-log bacterial kill in a neutropenic
system [21,22]. This would therefore imply that
a T > MIC > 40% should be bacteriologically
effective in pneumococcal infection in humans
and perhaps also for H. inﬂuenzae.
There is some evidence in human respiratory
tract infection to relate the T > MIC to bacterio-
logical outcome [23]. Craig and Andes, however,
reported a retrospective analysis of pooled data
from clinical studies of acute otitis media treated
with b-lactams, macrolides and trimethoprim-
sulfamethoxazole. The correlation with in-vitro
and animal data was not precise since these
human data implied added beneﬁt in terms of
bacteriological cure, because the T > MIC excee-
ded 40%. More human data for penicillins are
clearly needed.
THERAPEUTIC IMPLICATIONS
An unbound drug serum concentration present
for > 40–50% of the dosing interval has been taken
as predictive of bacteriological efﬁcacy for
b-lactams [24]. The implications of this are illus-
trated in Table 1, which shows the percentage of
the dosing interval that average serum amoxicillin
concentrations, after oral administration in
humans, will remain above the MICs of S. pneu-
moniae ranging from £ 0.06 to ‡ 16 mg ⁄L. Unsur-
prisingly, as the dose of amoxicillin increases, the
MIC of potentially treatable S. pneumoniae strains
also increases. The implication of Table 1 is that
S. pneumoniae strains with MICs of 2 mg ⁄L to
amoxicillin would respond to amoxicillin at a dose
of 1000 mg three times daily in a similar way to a
strain with an amoxicillin MIC of £ 0.06 mg ⁄L. An
extremely detailed study of pneumonia in immu-
nocompetent rabbits indicated that there was no
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Fig. 2. Theoretical plot of relationship between the
b-lactam T > MIC and eradication of a potential pathogen.
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difference in terms of mortality, histology, mac-
roscopic appearance, pneumococcal concentra-
tions in tissues or computed tomography scan
pneumonia appearances when penicillin-suscept-
ible (amoxicillin MIC £ 0.06 mg ⁄L) and -resistant
(amoxicillin MIC 2 mg ⁄L) S. pneumoniae was
treated with amoxicillin at concentrations de-
signed to be equivalent to 1000 mg three times
daily in humans [25]. Obviously, some caution
must be exercised in interpreting data of this
kind, because the mean concentrations do not
provide any information on the likely pharmaco-
kinetic variability that will be observed in infected
patients.
The degree of pharmacokinetic variability with
amoxicillin has recently been illustrated in a
study of 66 children under 60 months of age
admitted to hospital in Brazil with nonsevere
pneumonia [26]. The T > MIC on day 3 of therapy
with either a 15 mg ⁄ kg three times daily or
25 mg ⁄kg twice daily dose schedule for strains
with MIC values of 0.5, 1 or 2 mg ⁄L are shown in
Table 2. The range of T > MIC values for any
given MIC and dose schedule may vary consid-
erably, particularly when MICs are high. This
pharmacokinetic variability has recently been
postulated as a cause of breakthrough S. pneumo-
niae bacteraemia in patients receiving coamoxi-
clav (27). The use of Monte Carlo simulations in
predicting the likely antibacterial effect of differ-
ent dosing regimens allows this variability to be
taken into account. As yet, no simulations have
been performed to model the relative efﬁcacies of
different amoxicillin doses against S. pneumoniae.
PHARMACODYNAMICS OF
EMERGENCE OF RESISTANCE
Emergence of resistance to amoxicillin in
S. pneumoniae and the ability of penicillin to select
resistant strains have been investigated using
in-vitro models, and in mouse and rabbit infection
models [28,29]. The T > MIC and heterogeneity of
the S. pneumoniae population seem to have an
impact on the ability of amoxicillin ⁄ clavulanate to
produce amoxicillin-resistant S. pneumoniae
(Table 3) [28]. The strain that was more hetero-
geneously resistant to amoxicillin ⁄ clavulanate, as
indicated by its ability to grow on plates with
higher antibiotic concentrations, before exposure
to antibiotic was also more likely to produce
resistant populations when compared with the
nonheterogeneous strain. However, resistance
emerged only at low T > MIC drug exposure [28].
Knudsen et al. employed amixture ofS. pneumoniae
with MICs of 0.016, 0.25 and 4 mg ⁄L in mouse
thigh, peritonitis, rabbit tissue cage and in-vitro
models [29]. Maximum efﬁcacy was observed, as
expected, at a T > MIC of > 40–50% and also at a
peak ⁄MIC ratio of > 10. In all the model systems,
more resistant strains were selected from the
mixtures by insufﬁcient penicillin therapy; that is,
when the T > MICs were low. This correlates well
with the clinical experience in which carriage of
penicillin-nonsusceptible S. pneumoniae in the
Table 2. T > MIC (% of dose interval) for amoxicillin at
doses of 15 mg ⁄kg three times daily or 25 mg ⁄kg twice
daily for MIC values of 0.5, 1 and 2 mg ⁄L after 3 days of
therapy [26]
MIC (mg/L) Dose
T > MIC
Mean Range
0.5 15 mg ⁄kg three times daily 89 57–100
25 mg ⁄kg twice daily 76 40–100
1 15 mg ⁄kg three times daily 79 49–106
25 mg ⁄kg twice daily 65 37–100
2 15 mg ⁄kg three times daily 62 13–98
25 mg ⁄kg twice daily 51 12–100
Table 1. T > MIC (%) for various amoxicillin doses for a range of S. pneumoniae MICs in the range £ 0.06 to ‡ 16 mg ⁄L
Amoxicillin
dose (mg) Frequency
T > MIC (%) for each MIC assuming 8-hourly dosing
£ 0.06 0.12 0.25 0.5 1 2 4 8 ‡ 16
125 three times daily 100 86 71 54 35 11 0 0 0
250 three times daily 100 100 84 65 46 23 4 0 0
500 three times daily 100 100 100 74 57 40 24 0 0
875 twice daily 100 100 94 63 50 41 27 12 1
1000 three times daily 100 100 100 100 84 60 33 11 1
Dashed line denotes division of MICs into those for which, on average, the T > MIC is ‡ 40%.
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nasopharynx is associated with prior b-lactam use
(either penicillins or cephalosporins) [30]. It has
been suggested that longer, low-dose b-lactam
therapy may be worse in this regard [31]. Indeed,
a prospective, randomised study of short-course,
high-dose amoxicillin (90 mg ⁄ kg ⁄day twice daily
for 5 days) compared with long-course, lower-
dose treatment (40 mg ⁄ kg ⁄day twice daily for
10 days) in children with respiratory tract infec-
tion indicated that those who received high doses
for a shorter time were less likely to carry
penicillin-nonsusceptible S. pneumoniae after they
had completed therapy [32].
CONCLUSIONS
The present knowledge base allows for a good
understanding of the factors important in ensur-
ing good therapeutic outcomes when penicillins
are used to treat S. pneumoniae lower respiratory
tract infection. Exploitation of this knowledge
should allow for the use of amoxicillin ⁄ clavula-
nate dosing regimens that are satisfactory to treat
a wide range of S. pneumoniae strains—including
those presently classiﬁed as penicillin-nonsuscep-
tible. Short, high-dose regimens should also help
reduce the risks of emergence of resistance.
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